These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32929881)

  • 21. The effect of a polyurethane coating incorporating both a thrombin inhibitor and nitric oxide on hemocompatibility in extracorporeal circulation.
    Major TC; Brisbois EJ; Jones AM; Zanetti ME; Annich GM; Bartlett RH; Handa H
    Biomaterials; 2014 Aug; 35(26):7271-85. PubMed ID: 24927680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of haemodialysis membrane biocompatibility by parallel assessment in an ex vivo model in healthy volunteers.
    Mulvihill J; Crost T; Renaux JL; Cazenave JP
    Nephrol Dial Transplant; 1997 Sep; 12(9):1968-73. PubMed ID: 9306352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of catheter thrombogenicity in a modified chandler loop model using goat blood.
    Olsen AL; Long M
    J Biomed Mater Res A; 2018 Dec; 106(12):3143-3151. PubMed ID: 30194709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro blood compatibility of surface-modified polyurethanes.
    Bernacca GM; Gulbransen MJ; Wilkinson R; Wheatley DJ
    Biomaterials; 1998 Jul; 19(13):1151-65. PubMed ID: 9720899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel low-background noise blood loop model for testing blood-contacting biomaterials and medical devices in fresh human blood.
    Cahalan P; Hegy M; Cahalan L; Curry B; Ubl S; Jeffers H; Wolf MF
    J Biomed Mater Res B Appl Biomater; 2023 Jan; 111(1):38-50. PubMed ID: 35833248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An In Vitro Blood Flow Loop System for Evaluating the Thrombogenicity of Medical Devices and Biomaterials.
    Jamiolkowski MA; Hartung MC; Malinauskas RA; Lu Q
    ASAIO J; 2020 Feb; 66(2):183-189. PubMed ID: 30807378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Device thrombogenicity emulation: a novel method for optimizing mechanical circulatory support device thromboresistance.
    Girdhar G; Xenos M; Alemu Y; Chiu WC; Lynch BE; Jesty J; Einav S; Slepian MJ; Bluestein D
    PLoS One; 2012; 7(3):e32463. PubMed ID: 22396768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioreactivity of stent material: Activation of platelets, coagulation, leukocytes and endothelial cell dysfunction in vitro.
    Ollivier V; Roques C; Receveur N; Gratz M; Feldman L; Letourneur D; Gachet C; Mangin PH; Jandrot-Perrus M
    Platelets; 2017 Sep; 28(6):529-539. PubMed ID: 28032527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Polymer Hemocompatibility for Blood-Contacting Applications via
    Griffin L; Douglass M; Goudie M; Hopkins SP; Schmiedt C; Handa H
    ACS Appl Mater Interfaces; 2022 Mar; 14(9):11116-11123. PubMed ID: 35225600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA.
    Coli L; Cianciolo G; Feliciangeli G; De Sanctis LB; Zanchelli F; Dalmastri V; De Pascalis A; Sestigiani E; Donati G; Stefoni S
    Contrib Nephrol; 1999; 125():111-9. PubMed ID: 9895435
    [No Abstract]   [Full Text] [Related]  

  • 32. Fibrinogen binding and platelet retention: relationship with the thrombogenicity of catheters.
    Bailly AL; Laurent A; Lu H; Elalami I; Jacob P; Mundler O; Merland JJ; Lautier A; Soria J; Soria C
    J Biomed Mater Res; 1996 Jan; 30(1):101-8. PubMed ID: 8788111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombogenicity testing of central venous catheters in vitro.
    Böswald M; Lugauer S; Bechert T; Greil J; Regenfus A; Guggenbichler JP
    Infection; 1999; 27 Suppl 1():S30-3. PubMed ID: 10379440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel in vitro model for preclinical testing of the hemocompatibility of intravascular stents according to ISO 10993-4.
    Sinn S; Scheuermann T; Deichelbohrer S; Ziemer G; Wendel HP
    J Mater Sci Mater Med; 2011 Jun; 22(6):1521-8. PubMed ID: 21604053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
    Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
    Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Device thrombosis and pre-clinical blood flow models for assessing antithrombogenic efficacy of drug-device combinations.
    Sukavaneshvar S
    Adv Drug Deliv Rev; 2017 Mar; 112():24-34. PubMed ID: 27496706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Device Thrombogenicity Emulation: An In Silico Predictor of In Vitro and In Vivo Ventricular Assist Device Thrombogenicity.
    Chiu WC; Tran PL; Khalpey Z; Lee E; Woo YR; Slepian MJ; Bluestein D
    Sci Rep; 2019 Feb; 9(1):2946. PubMed ID: 30814674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes.
    Weber N; Wendel HP; Ziemer G
    J Biomater Appl; 2000 Jul; 15(1):8-22. PubMed ID: 10972157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surface modification of polymeric biomaterials with poly(ethylene oxide), albumin, and heparin for reduced thrombogenicity.
    Amiji M; Park K
    J Biomater Sci Polym Ed; 1993; 4(3):217-34. PubMed ID: 8476792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.